Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
Investing in emerging technologies can offer significant growth potential, but it’s important to remember they also come with higher risks due to the volatility of the tech sector.
For premium support please call: 800-290-4726 more ways to reach us
The issue is still subject of numerous studies, and prompting academic argument. That's mainly because the "energy invested" critically depends on technology, methodology, and system boundary assumptions, resulting in a range from a maximum of 2000 kWh/m 2 of module area down to a minimum of 300 kWh/m 2 with a median value of 585 kWh/m 2 according to a meta-study from 2013.
In December 2021, it was reported that the first CRISPR-gene-edited marine animal/seafood and second set of CRISPR-edited food has gone on public sale in Japan: two fish of which one species grows to twice the size of natural specimens due to disruption of leptin, which controls appetite, and the other grows to 1.2 the natural average size with ...
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. [ 8 ]
For premium support please call: 800-290-4726 more ways to reach us
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]